ライフサイエンスコーパス: diffuse large-cell lymphoma

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 rgroup phase 3 trial in recurrent/refractory diffuse large cell lymphoma.

2 se to treatment similar to that reported for diffuse large cell lymphoma.

3 intermediate- or high-grade lymphoma, 13 had diffuse large cell lymphoma.

4 or is frequently translocated and mutated in diffuse large cell lymphoma.

5 to its ability to transform B lymphocytes in diffuse large cell lymphoma.

6 ion of chronic lymphocytic leukemia (CLL) to diffuse large cell lymphoma.

7 re seen, prominently follicular lymphoma and diffuse large-cell lymphoma.

8 s in 24% (8 out of 34) activated B cell-like diffuse large cell lymphoma (ABC-DLBCL), but not in GC B

9 rmation of MALT lymphoma to activated B-cell diffuse large-cell lymphoma (ABC-DLBCL).

10 Virtually all diffuse large cell lymphomas and a significant fraction

11 me 1q21 are among the most common lesions in diffuse large-cell lymphoma and have been associated wit

12 The BCL-6 gene is involved in diffuse large-cell lymphoma and overexpressed in other t

13 Approximately 40% of diffuse large cell lymphoma are associated with chromoso

14 B cell diffuse large cell lymphoma (B-DLCL) is a heterogeneous

15 CL was morphologically more high grade (50% diffuse large cell lymphoma) compared with primary CL (3

16 In patients with diffuse large-cell lymphoma (DLBCL), we observed higher

17 nd large-cell lymphomas (DMxs), and 16 of 84 diffuse large-cell lymphomas (DLCCs); the difference bet

18 y chain disease case (MAL) and KI-1 positive diffuse large cell lymphoma (DLCL) cell line (KIS-1).

19 target of aberrant somatic hypermutation in diffuse large cell lymphoma (DLCL), the most common form

20 pression data set based on 160 patients with diffuse large cell lymphoma (DLCL).

21 o [OR] = 0.57; 0.34-0.94), particularly with diffuse large cell lymphoma (DLCL; OR = 0.29; 0.10-0.82)

22 In approximately 40% of diffuse large cell lymphomas (DLCL) and approximately 14

23 of all NHL and of two predominant subtypes, diffuse large-cell lymphoma (DLCL) (n = 233) and follicu

24 otypic features of 71 cases of primary CD30+ diffuse large-cell lymphomas (DLCL) and 128 cases of Hod

25 and various other partners are recurrent in diffuse large-cell lymphomas (DLCL).

26 ning for CPP32 was present in 10 of 12 (83%) diffuse large cell lymphomas (DLCLs) and 2 of 3 diffuse

27 hoH/TTF (ARHH) and PAX5, in more than 50% of diffuse large-cell lymphomas (DLCLs), which are tumours

28 s of FL showed morphologic transformation to diffuse large-cell lymphoma (DLL) in the second biopsy.

29 gated the molecular features of EBV-positive diffuse large cell lymphomas in 2 patients with RA.

30 lymphoma in patients with secondary CL were diffuse large cell lymphoma (n = 5, 28%), chronic lympho

31 icular lymphomas (37 of 40 cases) as well as diffuse large-cell lymphomas of B-cell type (35 cases) d

32 eaved lymphoma (P =.0005) and an increase in diffuse large cell lymphoma (P <.0001).

33 cluding 16 relapsed CLL and 9 RT (all proven diffuse large cell lymphoma) patients were enrolled, and

34 In patients with diffuse large-cell lymphoma, serum interleukin-6 levels

35 gkin's lymphoma and, in a subset of cases of diffuse large cell lymphoma, the mechanism of Bcl-6 over

36 eported cases of the non-Hodgkin's lymphoma, diffuse large cell lymphoma, there are translocations of

37 f 13 follicular small cleaved and five of 13 diffuse large cell lymphomas were KAI1 negative.

38 118 untreated patients with diffuse large-cell lymphoma who were enrolled in frontli

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。